We are live on
!
Find out more
AAA
Affinity Asset Advisors Portfolio holdings
AUM
$1.94B
1-Year Est. Return
374.45%
This Fund
S&P 500
This Quarter
Est. Return
-6.02%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$1.05B
AUM Growth
+$302M
(+40%)
Cap. Flow
+$392M
Cap. Flow
% of AUM
37.44%
Top 10 Holdings %
Top 10 Hldgs %
55.13%
Holding
117
New
33
Increased
29
Reduced
19
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travere Therapeutics
TVTX
|
+$17.7M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$17.6M |
| 3 |
NUVL
Nuvalent
NUVL
|
+$13.7M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$11.3M |
| 5 |
Mineralys Therapeutics
MLYS
|
+$8.63M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arvinas
ARVN
|
+$12.1M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$11.5M |
| 3 |
Spyre Therapeutics
SYRE
|
+$7.13M |
| 4 |
Arrowhead Research
ARWR
|
+$5.64M |
| 5 |
SLNO
Soleno Therapeutics
SLNO
|
+$3.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 55.37% |
| 2 | Financials | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
PUT
Mineralys Therapeutics
MLYS
$2.35B
| $3.18M | 0.3% |
+200,000
| New | +$2.3M |
|
52
PUT
ImmunityBio
IBRX
$7.44B
| $3.09M | 0.29% |
1,025,000
+775,000
| +310% | +$2.35M |
|
53
Akebia Therapeutics
AKBA
$327M
| $2.88M | 0.27% |
+1,500,000
| New | +$3.06M |
|
|
MAZE
54
Maze Therapeutics
MAZE
$1.53B
| $2.75M | 0.26% |
+250,000
| New | +$3.01M |
|
55
NewAmsterdam Pharma Warrant
NAMSW
| $2.75M | 0.26% |
241,957
+4,022
| +2% | +$43.9K |
|
56
Kymera Therapeutics
KYMR
$9.1B
| $2.74M | 0.26% |
100,000
+60,000
| +150% | +$2.19M |
|
|
OACCU
57
Oaktree Acquisition Corp III Life Sciences Unit
OACCU
| $2.6M | 0.25% |
250,000
| – | – |
|
58
PUT
Compass Therapeutics
CMPX
$373M
| $2.53M | 0.24% |
+1,330,700
| New | +$3.54M |
|
59
Geron
GERN
$911M
| $2.38M | 0.23% |
1,500,000
-750,000
| -33% | -$1.83M |
|
60
Monopar Therapeutics
MNPR
$736M
| $2.26M | 0.22% |
+62,000
| New | +$2.23M |
|
61
PUT
Galectin Therapeutics
GALT
$229M
| $2.24M | 0.21% |
1,836,200
-655,800
| -26% | -$920K |
|
62
Mirum Pharmaceuticals
MIRM
$6.89B
| $2.24M | 0.21% |
49,692
-21,050
| -30% | -$992K |
|
|
63
CALL
NewAmsterdam Pharma
NAMS
$3.47B
| $2.04M | 0.2% |
+99,800
| New | +$2.22M |
|
|
JBIO
64
Jade Biosciences
JBIO
$1.22B
| $2.01M | 0.19% |
22,857
| – | – |
|
65
Cullinan Oncology
CGEM
$1.05B
| $2M | 0.19% |
263,817
| – | – |
|
|
CLYM
66
Climb Bio
CLYM
$735M
| $1.83M | 0.17% |
1,500,000
+1,000,000
| +200% | +$1.62M |
|
|
OKUR
67
OnKure Therapeutics
OKUR
$166M
| $1.69M | 0.16% |
394,159
+250,000
| +173% | +$1.41M |
|
|
68
PUT
NewAmsterdam Pharma
NAMS
$3.47B
| $1.54M | 0.15% |
+75,000
| New | +$1.67M |
|
|
TRML
69
CALL
DELISTED
Tourmaline Bio
TRML
| $1.52M | 0.15% |
+100,000
| New | +$1.6M |
|
70
Roivant Sciences
ROIV
$25.2B
| $1.51M | 0.14% |
+150,000
| New | +$1.62M |
|
71
Nkarta
NKTX
$162M
| $1.47M | 0.14% |
800,000
| – | – |
|
|
AVR
72
Anteris Technologies
AVR
$791M
| $1.42M | 0.14% |
390,000
+90,000
| +30% | +$579K |
|
|
MBX
73
MBX Biosciences
MBX
$2.95B
| $1.29M | 0.12% |
+175,000
| New | +$1.85M |
|
|
THRD
74
DELISTED
Third Harmonic Bio
THRD
| $1.28M | 0.12% |
+370,000
| New | +$1.79M |
|
|
ETNB
75
DELISTED
89bio
ETNB
| $1.27M | 0.12% |
+175,000
| New | +$1.53M |
|
Similar funds
FM
1SB
HCL
OCM
HC
FFH
BC
WPC
Affinity Asset Advisors's Q1 2025 Portfolio in Review
As of Q1 2025, Affinity Asset Advisors held 117 positions worth $1.05B, up 40% from $746M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Affinity Asset Advisors deployed $392M of net new capital in Q1 2025, opening 33 new positions and adding to 29 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 30,000 shares worth $16.8M.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 78% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Crinetics Pharmaceuticals, an estimated $11.5M trimmed.
- Affinity Asset Advisors's largest Q1 2025 buy was State Street SPDR S&P 500 ETF Trust: 30,000 shares worth $16.8M.
- Affinity Asset Advisors added most to Travere Therapeutics in Q1 2025, an estimated $17.7M increase.
- Affinity Asset Advisors's biggest Q1 2025 reduction was Crinetics Pharmaceuticals, cutting an estimated $11.5M.
- Affinity Asset Advisors fully exited Arvinas in Q1 2025, selling an estimated $12.1M.
- Affinity Asset Advisors's ten largest holdings make up 55% of its $1.05B portfolio in Q1 2025.
- Affinity Asset Advisors opened 33 new positions and closed 19 in Q1 2025.
- Affinity Asset Advisors's portfolio value rose 40% quarter-over-quarter to $1.05B.
Based on Affinity Asset Advisors's 13F filing for Q1 2025, filed 14 May 2025.